Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain's ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain's ability to compensate for damage due to trauma or disease. The Company's PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone215-944-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Helius Medical Technologies (OTCMKTS:HSDT) Frequently Asked Questions
What is Helius Medical Technologies' stock symbol?
Helius Medical Technologies trades on the OTCMKTS under the ticker symbol "HSDT."
How were Helius Medical Technologies' earnings last quarter?
Helius Medical Technologies Inc (OTCMKTS:HSDT) released its quarterly earnings data on Thursday, March, 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.02. The firm earned $0.48 million during the quarter. View Helius Medical Technologies' Earnings History.
What guidance has Helius Medical Technologies issued on next quarter's earnings?
Helius Medical Technologies issued an update on its FY 2019 earnings guidance on Thursday, March, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1-2 million.
What price target have analysts set for HSDT?
2 brokers have issued 12 month price targets for Helius Medical Technologies' shares. Their forecasts range from $10.00 to $14.00. On average, they expect Helius Medical Technologies' share price to reach $12.00 in the next year. This suggests a possible upside of 311.0% from the stock's current price. View Analyst Price Targets for Helius Medical Technologies.
What is the consensus analysts' recommendation for Helius Medical Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Helius Medical Technologies.
Has Helius Medical Technologies been receiving favorable news coverage?
News stories about HSDT stock have trended neutral on Sunday, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Helius Medical Technologies earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of Helius Medical Technologies' key competitors?
Some companies that are related to Helius Medical Technologies include Rockwell Medical (RMTI), Cutera (CUTR), Electrocore (ECOR), Zynex (ZYXI), Edap Tms (EDAP), BioSig Technologies (BSGM), Fonar (FONR), Stereotaxis (STXS), Second Sight Medical Products (EYES), IRIDEX (IRIX), Soleno Therapeutics (SLNO), Viveve Medical (VIVE), Digirad (DRAD), Precision Optics (PEYE) and ENDRA Life Sciences (NDRA).
What other stocks do shareholders of Helius Medical Technologies own?
Who are Helius Medical Technologies' key executives?
Helius Medical Technologies' management team includes the folowing people:
- Philippe Deschamps, President, Chief Executive Officer, Director
- Joyce N. LaViscount, Chief Financial Officer, Chief Operating Officer
- Brian Bapty, Vice President, Strategy and Business Development
- Jonathan Sackier, Chief Medical Officer
- Dane Andreeff, Director
- Huaizheng Peng, Director
- Mitch Eugene Tyler, Director
- Thomas E. Griffin, Independent Director
- Edward M. Straw, Independent Director
How do I buy shares of Helius Medical Technologies?
Shares of HSDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Helius Medical Technologies' stock price today?
One share of HSDT stock can currently be purchased for approximately $2.92.
How big of a company is Helius Medical Technologies?
Helius Medical Technologies has a market capitalization of $68.28 million.
What is Helius Medical Technologies' official website?
How can I contact Helius Medical Technologies?
Helius Medical Technologies' mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The company can be reached via phone at 215-944-6100 or via email at [email protected]
MarketBeat Community Rating for Helius Medical Technologies (OTCMKTS HSDT)
MarketBeat's community ratings are surveys of what our community members think about Helius Medical Technologies and other stocks. Vote "Outperform" if you believe HSDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
